Galecto, Inc.

Galecto is a clinical-stage biotechnology business dedicated on the discovery and development of innovative small molecule medicines targeting at biological targets at the heart of fibrosis, inflammation, and cancer.

Galecto was formed in 2011 by top fibrosis scientists and biotech executives from Sweden, the United Kingdom, and Denmark, and it is based on more than a decade of study into galectin and fibrosis modulators.

The company is based on more than a decade of study into the roles of galectin-3 and LOXL-2, as well as the usage of modulators of these proteins to cure fibrosis and cancer. These assets, when combined with a robust patent portfolio, provide Galecto with a distinct treatment platform.

Galecto's primary product candidate, GB0139, is an inhaled galectin-3 inhibitor. GB0139 is being developed to treat severe fibrotic lung disorders such as idiopathic pulmonary fibrosis (IPF), where there is a significant unmet medical need. GB1211, an orally delivered galectin-3 inhibitor for the treatment of systemic fibrotic diseases such as liver cirrhosis, is also in the company's pipeline, as is GB2064, an inhibitor of lysyl oxidase like 2, or LOXL2, an enzyme directly involved in the formation of fibrosis that we plan to develop first in myelofibrosis.

Novo Holdings, OrbiMed, Ysios, HBM Healthcare Investments, Sunstone Capital, M Ventures, Bristol-Myers Squibb, Maverick Ventures, Seventure, and SEED Capital have all invested in Galecto.

Founded: 2011

Headquarters: Copenhagen, Denmark

Website: https://galecto.com/